Department of Biotechnology, Norwegian University of Science and Technology, Sem Sælands Vei 6/8, 7491 Trondheim, Norway.
J Biotechnol. 2012 Apr 30;158(4):168-75. doi: 10.1016/j.jbiotec.2011.06.002. Epub 2011 Jun 12.
Many representatives of the order Actinomycetales are prolific producers of thousands of biologically active secondary metabolites. Actinomycetes from terrestrial sources have been studied and screened since the 1950s, yielding many important anti-infective and anti-cancer drugs. However, frequent re-discovery of the same compounds in terrestrial actinomycetes have made them less attractive for screening programs in the recent years. At the same time, actinomycetes isolated from the marine environment currently receive considerable attention due to the structural diversity and unique biological activities of their secondary metabolites. This review highlights achievements and challenges in the isolation of marine actinomycetes, some examples of bioactive metabolites identified by conventional screening, and presents new developments in the field of genome mining and heterologous expression of biosynthetic gene clusters leading to the discovery of novel compounds.
许多放线菌目(Actinomycetales)的代表种是成千上万种生物活性次生代谢产物的丰富生产者。自 20 世纪 50 年代以来,人们一直在研究和筛选来自陆地来源的放线菌,从中产生了许多重要的抗感染和抗癌药物。然而,陆地放线菌中相同化合物的频繁重新发现,使得它们在近年来的筛选计划中吸引力降低。与此同时,由于其次生代谢产物的结构多样性和独特的生物活性,从海洋环境中分离出的放线菌目前受到了相当大的关注。本文重点介绍了海洋放线菌分离方面的成就和挑战,介绍了通过常规筛选鉴定的一些生物活性代谢产物的实例,并介绍了基因组挖掘和生物合成基因簇异源表达领域的新进展,这些进展导致了新型化合物的发现。